Phenytoin dose adjustment in epileptic patients

Area of Science:

• Pharmacokinetics
• Clinical Pharmacology
• Epilepsy Management

Background:

• Many epilepsy outpatients exhibit subtherapeutic serum phenytoin concentrations (below 10-20 μg/ml), despite treatment.
• This indicates a need for personalized dosing strategies to optimize therapeutic efficacy.

Purpose of the Study:

• To develop and evaluate a phenytoin tolerance test for predicting adequate daily phenytoin sodium doses.
• To utilize Michaelis-Menten kinetics for individualizing phenytoin dosage in epilepsy patients.

Main Methods:

• A phenytoin tolerance test involving a 600 mg oral dose was administered to 15 epilepsy patients.
• Serum phenytoin concentrations were measured over 48 hours and analyzed using Michaelis-Menten kinetics via an iterative computer program.
• The study determined the mean saturated rate of elimination and K(m) for phenytoin.

Main Results:

• The mean saturated rate of phenytoin elimination was 435 mg/day, with a K(m) of 3.8 μg/ml.
• Predicted daily doses for a steady-state concentration of 10-20 μg/ml ranged from 345-400 mg/day.
• Predicting steady-state concentrations using larger dose increments (100 mg) proved inaccurate, suggesting smaller adjustments (25 mg) are necessary once concentrations reach 5-10 μg/ml.

Conclusions:

• The phenytoin tolerance test, incorporating Michaelis-Menten kinetics, can predict optimal daily phenytoin sodium dosage.
• Individualized dosing adjustments, particularly smaller increments, are crucial for achieving and maintaining therapeutic phenytoin serum concentrations.
• This approach aids in optimizing epilepsy management by ensuring adequate drug levels.